Is Pfizer's new R&D plan doomed to failure?

Pfizer garnered headlines recently when it announced plans to launch a new innovation center that will create teams of academic and pharma researchers in the Boston area, one of the world's hottest biotech hubs. Xconomy's Luke Timmerman talked with one of the principals, and came away highly doubtful of the project's success. Academia and pharma have radically different cultures, he maintains, which rarely work well together. But if it is a success, Pfizer can get up to 30 percent of its early-stage work done through the program and just might create a whole new R&D template for the field. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.